



**BILLING CODE: 5001-03**

**DEPARTMENT OF DEFENSE**

**Department of the Army**

**Intent to Grant an Exclusive License for U.S. Government-Owned Invention**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable biological materials license.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command,  
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, MD  
21702-5012.

**FOR FURTHER INFORMATION CONTACT:** Mr. Barry Datlof, Office of Research & Technology Applications, (301) 619-0033, telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable biological materials license to 45AZ Dengue-1 strain to PrimeVax Immuno-Oncology, Inc., having its principal place of business at 2229 W. Mills Drive, Orange, California 92868.

Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication.

Written objections are to be filed with the Command Judge Advocate (see **ADDRESSES**).

**Brenda S. Bowen,**

*Army Federal Register Liaison Officer.*

[FR Doc. 2018-21152 Filed: 9/27/2018 8:45 am; Publication Date: 9/28/2018]